+0.05(+0.34%)

-0.0001(-0.0113%)

CORAL SPRINGS, FL--(Marketwire - 09/27/10) - Nutra Pharma Corporation (OTC.BB:NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, introduced today Nyloxin for Pets, a new pain reliever aimed at treating moderate to severe chronic pain in companion animals."Companion animals play an important role in our homes and communities and are, oftentimes, considered extended members of the family," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As pet owners, many of us will seek out new, innovative and safe treatments for our pets as they become older and less agile. I believe that both pet owners and veterinarians will prefer the safety and efficacy profile offered by Nyloxin for Pets over alternative pain relievers that contain opiates, acetaminophen and other potentially harmful pharmaceutical ingredients," he added.According to a 2009 survey conducted by the American Pet Products Association, 93.6 million cats and 77.5 million dogs were owned as pets in the United States. Additionally, the same report published sales for pet supplies, including over-the-counter medicines, totaling $10.48 billion for the same period."Nyloxin for Pets offers the opportunity to expand our Nyloxin brand into the large and growing animal health and wellness industry," explained David Isserman, Chief Marketing Officer of Nutra Pharma Corporation. "As we move forward with this launch, we plan to align ourselves with qualified pet care distributors that can provide the necessary support for national market penetration," he concluded.Nyloxin for Pets will be available in an everyday strength sold through retailers and in an extra strength sold only through veterinarian offices. Additionally, Nyloxin for Pets will be specifically formulated to treat moderate to severe chronic pain from hip dysplasia, arthritis, and joint inflammation.About Nutra Pharma Corp. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com.SEC Disclaimer This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Introducing Nyloxin for Pets should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.